Purpose: To investigate the short-term effectiveness of oxaliplatin in the interventional treatment of liver cancer, and its effect on serum CD163 and alpha-L-glucosidase (AFU). Methods: Eighty liver carcinoma patients treated in The Affiliated Hospital of Shaoxing University, Shaoxing, China from January 2022 to January 2023 were allotted to 2 cohorts (each with 40 patients). Subjects in control group were treated with hepatic Transarterial Chemoembolization (TACE), while study group was treated with combination of hepatic TACE and oxaliplatin. Efficacy, serological indicators, health status and cancer-related fatigue were determined and compared between both cohorts. Results: DCR was significantly higher in study group than in the control. There were significantly reduced post-treatment amounts of CYFRA21-1, CA125 and VGEF in the study cohort, relative to pre-treatment and control levels (p < 0.05). Post-treatment values of CD4+/CD8+ and CD4+ were significantly low, relative to levels before treatment, while CD8+ in both groups were significantly increased after treatment (p < 0.05). However, post-treatment T lymphocyte level was comparable in both groups. There was significantly higher post-treatment KPS score in study cohort than pre-treatment and control scores, but RPFS score was significantly reduced, relative to the corresponding pre-treatment and control scores. Post-treatment serum amounts of CD163 and AFU were significantly down-regulated in both cohorts, with lower levels in the study cohort. Conclusion: The combined use of liver TACE and oxaliplatin produces good clinical outcome in the treatment of liver cancer. It is beneficial in reducing serum levels of CD163 and AFU, inhibits proliferation of tumor cells, reduces tumor volume, and improves cancer prognosis in patients
